Plasma samples were drawn at enrollment, not hospital presentation. 4 days subhazard ratio, 0.51 ), with subhazard ratios similar across all levels of baseline pulmonary severity. Plasma antigen level of 1000 ng/L or greater was associated with a markedly higher odds of worsened pulmonary status at day 5 (odds ratio, 5.06 ) and longer time to hospital discharge (median, 7 vs. In contrast, race, ethnicity, body mass index, and immunocompromising conditions were not associated with plasma antigen levels. Additional factors associated with higher baseline antigen level included male sex, shorter time since hospital admission, decreased days of remdesivir, and renal impairment. Plasma antigen level was higher in those who lacked antispike antibodies (6.42 fold CI, 5.37 to 7.66) and in those with the Delta variant (1.73 fold CI, 1.41 to 2.13). Baseline pulmonary severity of illness was strongly associated with plasma antigen level, with mean plasma antigen level 3.10-fold higher among those requiring noninvasive ventilation or high-flow nasal cannula compared with room air (95% CI, 2.22 to 4.34). Plasma antigen was below the level of quantification in 5% of participants at enrollment, and 1000 ng/L or greater in 57%. Association between elevated baseline antigen level of 1000 ng/L or greater and outcomes, including worsening of ordinal pulmonary scale at day 5 and time to hospital discharge, were evaluated using logistic regression and Fine-Gray regression models, respectively. Associations between baseline patient characteristics and viral factors and baseline plasma antigen levels were assessed using both unadjusted and multivariable modeling. Delta variant status was determined from baseline nasal swabs using reverse transcriptase polymerase chain reaction. To evaluate whether levels of plasma antigen can predict short-term clinical outcomes and identify clinical and viral factors associated with plasma antigen levels in hospitalized patients with SARS-CoV-2.Ĭross-sectional study of baseline plasma antigen level from 2540 participants enrolled in the TICO (Therapeutics for Inpatients With COVID-19) platform trial from August 2020 to November 2021, with additional data on day 5 outcome and time to discharge.Īdults hospitalized for acute SARS-CoV-2 infection with 12 days or less of symptoms.īaseline plasma viral N antigen level was measured at a central laboratory. Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important biomarker in patients with COVID-19 and enhance our understanding of the pathogenesis of COVID-19.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |